投稿信息
投稿信息
审稿周期
投稿命中率
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
3.9 %
年文章数
439
作者需知
暂无数据
NCBI查询
偏重的研究方向
暂无数据
期刊简介
稿件收录要求
稿件收录要求
Published by Adis International Limited (now part of Wolters Kluwer Health).
ISSN: 1173-8804.
BioDrugs keeps you up to date with the latest developments in the clinical application of biotechnology for the treatment of human disease.BioDrugs publishes high quality, peer-reviewed research and up- to-date, critical reviews on the clinical development and therapeutic application of biotechnology-based pharmaceuticals, diagnostic products, and innovative technologies. The journal is an essential resource for R & D professionals in the biomedical science industries and academia, and clinicians with an interest in the leading edge technology in this exciting area.
BioDrugs keeps you up to date with the latest developments in the clinical application of biotechnology for the treatment of human disease.BioDrugs publishes high quality, peer-reviewed research and up- to-date, critical reviews on the clinical development and therapeutic application of biotechnology-based pharmaceuticals, diagnostic products, and innovative technologies. The journal is an essential resource for R & D professionals in the biomedical science industries and academia, and clinicians with an interest in the leading edge technology in this exciting area.
